Vaccine Market Share by Company

Track the global vaccines sector. GSK, Merck, Pfizer, and Sanofi still collect most branded revenue through Shingrix, Gardasil, Prevnar, and Beyfortus, while Moderna and BioNTech fight the seasonal COVID, RSV, and flu market on mRNA. The investment story is franchise mix (respiratory versus endemic), ACIP and Gavi as demand switches, and a pipeline that is now oncology option-value after the CMV Phase 3 miss and a norovirus Phase 3 interim analysis that did not meet early-success criteria.

Data updated 2026-11-01
Vaccines

The Vaccines sector on Sterling tracks 20 companies.

Vaccines at a Glance

Eight issuer-reported 2025 figures. Four diversified P&Ls still dwarf the mRNA names. Consultant TAM stays out of this strip.

GSK vaccines 2025
£9.157B
+2% CER. Shingrix £3.558B, meningitis £1.583B, Arexvy £593M, established £3.120B.
GSK FY 2025
Merck vaccines 2025
$10.711B
Down from $13.448B. Almost entirely a Gardasil China destock.
Merck Q4 2025
Sanofi vaccines 2025
€7.936B
-1.2% CER. PPH €2.554B, flu/COVID €2.314B, Beyfortus €1.781B.
Sanofi FY 2025
Prevnar family 2025
$6.494B
Pfizer's number-two product. PCV20 adult and pediatric.
Pfizer 2025 performance
Comirnaty 2025
$4.367B
Pfizer-booked COVID vaccine sales. Seasonal, not an APA world.
Pfizer 2025 performance
Gardasil 2025
$5.233B
-39% year on year. US grew 9%; China destocked.
Merck Q4 2025
Moderna company 2025
$1.94B
Spikevax, mNEXSPIKE, mRESVIA. Targeting up to 10% growth in 2026.
Moderna FY 2025
Beyfortus 2025
€1.781B
+9.5% CER. Infant RSV monoclonal, not a vaccine. Sanofi/AstraZeneca.
Sanofi FY 2025

Top Vaccine Franchises, 2025

Named product and franchise sales in USD billions. GBP and EUR converted at IRS 2025 yearly average rates. Color is platform, not company.

Vaccine-Attributable Revenue by Company, 2025

Six public P&Ls, not a summed TAM. GSK, Merck, and Sanofi are issuer vaccines lines. Pfizer is Prevnar plus Comirnaty plus Abrysvo.

2025 Sales by Platform

Classified 2025 sales for GSK, Pfizer, Merck, Sanofi, and Moderna. Other/mixed is pediatric, flu, and residual books that are not a single platform.

Vaccines Public-Equity Universe by Archetype

Eighteen public roster members plus Serum Institute and Bharat Biotech (private), grouped by how they make money in vaccines.

Incumbents

The four diversified vaccines P&Ls. Most branded dollars still sit here.

GSK$GSKUK
Pfizer$PFEUS
Merck & Co.$MRKUS
Sanofi$SNYFR

mRNA platforms

COVID residual plus RSV and flu. Pipeline option-value is now oncology after the CMV Phase 3 miss and a norovirus Phase 3 interim analysis that did not meet early-success criteria.

Moderna$MRNAUS
BioNTech$BNTXDE
Arcturus Therapeutics$ARCTUS

Flu and protein specialists

Seqirus is the number-two flu manufacturer. Novavax is Nuvaxovid plus Matrix-M: total revenue was $1,123M in 2025 and its 2026 Adjusted Total Revenue framework is $235M to $275M.

CSL$CSL.AXAU
Novavax$NVAXUS

Regional, travel, biodefense

Japan/dengue (Takeda), mpox and chikungunya (Bavarian, Valneva), anthrax stockpile (Emergent). Different buyer, different cycle.

Takeda$TAKJP
Bavarian Nordic$BAVA.CODK
Valneva$VALNFR
Emergent BioSolutions$EBSUS

Infant RSV adjacency

AstraZeneca co-commercializes Beyfortus with Sanofi. Dual-homed on GLP-1.

AstraZeneca$AZNUK

China commercial

Zhifei is the cautionary tale for tender-market concentration after the Gardasil destock.

Zhifei Biological$300122.SZCN

Supply chain

Sterile fill-finish (Thermo Fisher), elastomer components (West), mRNA/LNP CDMO (Lonza). Shared calendar with GLP-1 pens.

Thermo Fisher Scientific$TMOUS
West Pharmaceutical Services$WSTUS
Lonza$LONN.SWCH

Volume manufacturers (private)

Dose volume, not branded P&L. Serum Institute is the Gavi/UNICEF backbone. Bharat is the second India name.

Serum Institute of IndiaprivateIN
Bharat BiotechprivateIN

End-to-End Vaccine Stack

Seven layers from antigen to use case. Bar fill is a display weight, not volume share. Fill-finish overlaps the GLP-1 calendar.

1

Antigen / drug substance

GSK in-house
Sanofi in-house
Pfizer / BioNTech mRNA
Moderna in-house
Merck in-house
Serum Institute
Seqirus (egg / cell)
2

Lipids and adjuvants

Acuitas (LNP IP)
CordenPharma lipids
GSK AS01
Novavax Matrix-M
Dynavax CpG 1018
3

Fill-finish

Pfizer sites
Moderna sites
Sanofi sites
Lonza
Thermo Fisher (Patheon)
Serum Institute
4

Components

West Pharma
Becton Dickinson
Schott vials
Syringes / PFS
5

Brand

Prevnar
Gardasil
Shingrix
Comirnaty / Spikevax
Beyfortus
Arexvy / Abrysvo
6

Buyer

CDC / VFC
National immunization programs
Gavi / UNICEF
Retail pharmacy
BARDA / SNS
7

Use case

Pediatric routine
Adult endemic
Respiratory seasonal
Infant RSV mAb
Travel / biodefense

Sector Milestones, 2020 to 2026

From COVID EUAs to the 2026 seasonal market: ACIP RSV votes, infant mAbs, the CMV Phase 3 miss, the norovirus interim analysis, platform M&A, and mFLUSIVA.

Oct 2025
ClinicalModerna

Moderna's Phase 3 CMV vaccine (mRNA-1647) misses its primary efficacy endpoint; congenital CMV program discontinued (22 Oct 2025)

Still no vaccine to prevent congenital CMV. mRNA-1647 continues only in a Phase 2 trial of bone marrow transplant patients.

Dec 2025
DealBioNTech / Sanofi

BioNTech's CureVac exchange offer completes with about 86.75% of shares tendered (18 Dec 2025), ahead of a compulsory acquisition of the rest in early January 2026; Sanofi agrees to buy Dynavax for $15.50 a share, about $2.2B in equity value (agreement 23 Dec 2025, announced 24 Dec 2025)

BioNTech adds to its mRNA design, delivery and manufacturing capabilities; Sanofi adds the marketed adult hepatitis B vaccine Heplisav-B and a Phase 1/2 shingles candidate. Sanofi completed the Dynavax acquisition on 10 Feb 2026.

Jan 2026
DealNovavax / Pfizer

Novavax grants Pfizer a non-exclusive worldwide Matrix-M adjuvant license for one infectious disease, with a second at Pfizer's option: $30M upfront, up to $500M in milestones across both fields (agreement dated 15 Jan 2026)

Adjuvant becomes a separate cash story from Nuvaxovid COVID volumes, with tiered high mid-single-digit royalties on top.

Mar 2026
DealBavarian Nordic

Bavarian Nordic and Serum Institute of India sign a contract manufacturing agreement for a full tech transfer of the chikungunya vaccine (CHIKV VLP, Vimkunya), announced 11 Mar 2026

Supply to low- and middle-income countries is to be scaled through Serum Institute, replacing the earlier agreement with Biological E.

9 Jul 2026
ProcurementModerna

European Commission announces a joint procurement framework contract with Moderna for up to 24 million mRESVIA doses, signed at the request of 6 countries, with no minimum purchase and a term of up to four years

Public-sector volume for adult RSV in Europe is a ceiling, not a commitment.

5 Aug 2026
ApprovalModerna

FDA approves mFLUSIVA (mRNA-1010) for adults 50+

First US mRNA seasonal flu shot. Traditional approval 50-64; accelerated approval 65+, with a required confirmatory study against high-dose flu vaccine. Demand depends on an ACIP recommendation and 2026-27 contracting.

19 Aug 2026
ClinicalModerna / Merck

Phase 3 INTerpath-001 of intismeran autogene (mRNA-4157) plus Keytruda in resected stage IIB-IV melanoma meets its primary endpoint of RFS and key secondary endpoint of DMFS at an interim analysis

Per the companies, the first positive Phase 3 for an individualized neoantigen therapy and for an mRNA cancer therapy. Detailed results on 22 Oct 2026 (ESMO late-breaker LBA1): 42% lower risk of recurrence or death (HR 0.58, 95% CI 0.45 to 0.75) and 38% lower risk of distant metastasis or death (HR 0.62, 95% CI 0.45 to 0.85) versus Keytruda alone; overall survival not yet mature. Phase 2b five-year data (20 Jan 2026) showed a 49% cut in recurrence or death versus Keytruda alone.

27 Aug 2026
ApprovalPfizer / BioNTech / Moderna

FDA approves 2026-2027 Formula COVID-19 vaccines: Comirnaty, Spikevax and mNEXSPIKE (FDA advised a monovalent JN.1-lineage XFG formula)

Comirnaty is approved for adults 65+ and ages 5 to 64 with a high-risk condition. On 28 Aug 2026 Novavax announced its partners' XFG-adapted Nuvaxovid was approved in the US, EU and Japan.

Frequently asked questions

What is the Vaccines sector?

Track the global vaccines sector. GSK, Merck, Pfizer, and Sanofi still collect most branded revenue through Shingrix, Gardasil, Prevnar, and Beyfortus, while Moderna and BioNTech fight the seasonal COVID, RSV, and flu market on mRNA. The investment story is franchise mix (respiratory versus endemic), ACIP and Gavi as demand switches, and a pipeline that is now oncology option-value after the CMV Phase 3 miss and a norovirus Phase 3 interim analysis that did not meet early-success criteria.

Which companies lead the Vaccines sector?

Sterling tracks 20 companies in Vaccines, led by GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).

How can I invest in the Vaccines sector?

Publicly traded names in Vaccines include GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY) and Moderna (MRNA). Compare them side by side on Sterling. Data last updated November 1, 2026.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites